Progress and problems with the use of viral vectors for gene therapy
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Gene therapy has a history of controversy. Encouraging results are starting to emerge from the clinic, but questions are still being asked about the safety of this new molecular medicine. With the development of a leukaemia-like syndrome in two of the small number of patients that have been cured of a disease by gene therapy, it is timely to contemplate how far this technology has come, and how far it still has to go.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Thomas et al., 2003
Citations
Cites
Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 Disease
Cavazzana-Calvo, M., Hacein-Bey, S., Basile, G. D. S., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J.-L., et al. (2000) · Science · doi:10.1126/science.288.5466.669 · Cited by 2,167 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundA serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“Recent evidence from a number of separate studies has challenged our perceptions about the risks of using integrating retrovirus vectors for certain types of gene therap”
BackgroundHIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 1×
“AAV vector genomes flanked by AAV2 inverted terminal repeats (ITRs) have also been successfully cross-packaged in the capsids of alternative serotypes, creating a portfolio of pseudotypes with different specificitie”
BackgroundRubinson, D. A., Dillon, C. P., Kwiatkowski, A. V., Sievers, C., Yang, L., Kopinja, J., Rooney, D. L., Zhang, M., Ihrig, M. M., McManus, M. T., et al. (2003) · Nature Genetics · doi:10.1038/ng1117 · Cited by 1,501
Naldini, L., Blömer, U., Gage, F. H., Trono, D., & Verma, I. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11382 · Cited by 1,499 · cited 1×
“They have proven to be effective tools for gene delivery to the central nervous system (CNS), generating long-term gene expression in the absence of inflammatio”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Self-citationKordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251 · cited 1×
“gov/htbin-post/Omim/dispmim?168600">Parkinson disease”
Cited by
Non-viral vectors for gene-based therapy
Yin, H., Kanasty, R. L., Eltoukhy, A. A., Vegas, A. J., Dorkin, J. R., & Anderson, D. G. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3763 · Cited by 3,123
Base editing: precision chemistry on the genome and transcriptome of living cells
Rees, H. A., & Liu, D. R. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0059-1 · Cited by 1,675
MicroRNA: Biogenesis, Function and Role in Cancer
MacFarlane, L.-A., & R. Murphy, P. (2010) · Current Genomics · doi:10.2174/138920210793175895 · Cited by 1,584
“While some vectors have been useful in animal studies they are not ideal for human because they can elicit an immune response that deflates their effectiveness [371-373].”
BackgroundNanochemistry and Nanomedicine for Nanoparticle-based Diagnostics and Therapy
Chen, G., Roy, I., Yang, C., & Prasad, P. N. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00148 · Cited by 1,499
Theranostics: Combining Imaging and Therapy
Kelkar, S. S., & Reineke, T. M. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200151q · Cited by 1,385
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
“In all cases of leukemia, the SCID X-1 correcting gene had inserted into the patient genome within or near tumor-promoting genes and caused transcriptional activation (Check, 2002; Kaiser, 2003; Thomas et al., 2003).”
BackgroundBiomedical applications of functionalised carbon nanotubes
Bianco, A., Kostarelos, K., Partidos, C. D., & Prato, M. (2005) · Chemical Communications · doi:10.1039/b410943k · Cited by 1,086
Carbon nanotube applications for tissue engineering
Harrison, B. S., & Atala, A. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2006.07.044 · Cited by 1,068
Emerging Frontiers in Drug Delivery
Tibbitt, M. W., Dahlman, J. E., & Langer, R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09974 · Cited by 975
Clinical use of lentiviral vectors
Milone, M. C., & O’Doherty, U. (2018) · Leukemia · doi:10.1038/s41375-018-0106-0 · Cited by 930
“U5 lopR R3UTPPvnegagPBSU5R pol cPPT cPPT tRNA tRNA cPPT cPPT cPPT cFLAP gag env PPT U3 RPBS pol gag env PPT U3 RPBS pol gag env PPT U3 RPBS pol gag env PPT U3 LTR RNA-DNA duplex U3 RPBSU5 U5 U5 U5 lopR RT RT LTR RT RT RT Fig.”
BackgroundInfluentialIn vitro and ex vivo strategies for intracellular delivery
Stewart, M. P., Sharei, A., Ding, X., Sahay, G., Langer, R., & Jensen, K. F. (2016) · Nature · doi:10.1038/nature19764 · Cited by 885
Singh, R., Pantarotto, D., McCarthy, D., Chaloin, O., Hoebeke, J., Partidos, C. D., Briand, J.-P., Prato, M., Bianco, A., & Kostarelos, K. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0441561 · Cited by 759
Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts
Stewart, M. P., Langer, R., & Jensen, K. F. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00678 · Cited by 747
Mesoporous silica nanoparticles for drug and gene delivery
Zhou, Y., Quan, G., Wu, Q., Zhang, X., Niu, B., Wu, B., Huang, Y., Pan, X., & Wu, C. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.007 · Cited by 706
Virus entry: molecular mechanisms and biomedical applications
Dimitrov, D. S. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro817 · Cited by 701
“Rhabdoviridae ssRNA Enveloped Rabies virus Endocytosis, acetylcholine Rabies (11-15) (45-100) receptor, neural cell adhesion molecule”
BackgroundLee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
“The majority of these studies have utilized adenoviral vectors largely because transient expression is more advantageous than constitutive expression in bone tissue engineering.(213,218) This approach utilizes adenoviral vectors containing genes that code for essential osteoinductive growth factors.”
BackgroundState-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
“The various vectors' history, creation and use have been reviewe”
BackgroundSelf-citationMicroglia in health and disease
Kim, S. U., & de Vellis, J. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20562 · Cited by 663
mRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
“However, several limitations are generally associated with these vectors, including immunogenicity,[14] carcinogenesis,[15] broad tropism,[16] packaging capacity,[17] and”
BackgroundSelf-assembled peptide-based nanostructures: Smart nanomaterials toward targeted drug delivery
Habibi, N., Kamaly, N., Memic, A., & Shafiee, H. (2016) · Nano Today · doi:10.1016/j.nantod.2016.02.004 · Cited by 619
Magnetite nanoparticles for cancer diagnosis, treatment, and treatment monitoring: recent advances
Revia, R. A., & Zhang, M. (2016) · Materials Today · doi:10.1016/j.mattod.2015.08.022 · Cited by 612
Prime editing for precise and highly versatile genome manipulation
Chen, P. J., & Liu, D. R. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-022-00541-1 · Cited by 605
Towards safe, non-viral therapeutic gene expression in humans
Glover, D. J., Lipps, H. J., & Jans, D. A. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1577 · Cited by 598
“, viral-based vectors urgently need to be reassessed with regard to their safety for human gene therap”
BackgroundKang, Q., Sun, M. H., Cheng, H., Peng, Y., Montag, A. G., Deyrup, A. T., Jiang, W., Luu, H. H., Luo, J., Szatkowski, J. P., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302298 · Cited by 575
Nanomaterials for Neural Interfaces
Kotov, N. A., Winter, J. O., Clements, I. P., Jan, E., Timko, B. P., Campidelli, S., Pathak, S., Mazzatenta, A., Lieber, C. M., Prato, M., et al. (2009) · Advanced Materials · doi:10.1002/adma.200801984 · Cited by 504
mRNA-based cancer therapeutics
Liu, C., Shi, Q., Huang, X., Koo, S., Kong, N., & Tao, W. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00586-2 · Cited by 500
Brown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484
“Currently, one of the major barriers to stable gene transfer is the development of transgene-specific immunit”
BackgroundConstruction and Characterization of Virus-Like Particles: A Review
Zeltins, A. (2013) · Molecular Biotechnology · doi:10.1007/s12033-012-9598-4 · Cited by 478
“Mammalian VLPs recognize cells from the corresponding organism and are able to deliver cargo, such as therapeutic nucleic acids or proteins, to the recipient organism [112, 113].”
BackgroundNitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities
Mocellin, S., Bronte, V., & Nitti, D. (2007) · Medicinal Research Reviews · doi:10.1002/med.20092 · Cited by 478
“Last, both retroviral and adenoviral vector maybe hazardous to the host and pose amajor health and safety risk.(252) A potential strategy to overcome the issues is to adopt a cell-based approach that delivers recombinant cells (rather than genes) to the target site, which has the advantage of optimizing gene expressio…”
BackgroundDelivery of bioactive molecules into the cell: the Trojan horse approach
Dietz, G. P. H., & Bähr, M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.03.005 · Cited by 469
Quantitative evolutionary dynamics using high-resolution lineage tracking
Levy, S. F., Blundell, J. R., Venkataram, S., Petrov, D. A., Fisher, D. S., & Sherlock, G. (2015) · Nature · doi:10.1038/nature14279 · Cited by 460
HUNTER, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.008 · Cited by 456
“Early clinical trails using recombinant viral vectors indicated significant problems primarily as they demonstrated short-lived transgene expression, an inability to persist in host cells and toxicity [1].”
BackgroundDNA Transposons: Nature and Applications in Genomics
Munoz-Lopez, M., & Garcia-Perez, J. (2010) · Current Genomics · doi:10.2174/138920210790886871 · Cited by 447
“For example, viral vectors may induce a destructive immune response [150, 151], their production is difficult and expensive [152, 153], they prefer to integrate within 5’UTR regions of genes which may induce oncogenesis [150, 154, 155], and they have a relatively limited cargo capacity (less than 8 kb in lentivirus, r…”
BackgroundChiappini, C., De Rosa, E., Martinez, J. O., Liu, X., Steele, J., Stevens, M. M., & Tasciotti, E. (2015) · Nature Materials · doi:10.1038/nmat4249 · Cited by 446
Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment
Mader, J. S., & Hoskin, D. W. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.933 · Cited by 430
“Unfortunately, the use of adenovirus or retroviral vectors for gene therapy is complicated by the inherent immunogenicity of viral expression vectors, the risk of developing cancer because of inadvertent oncogene activation caused by retrovirus integration and the difficulty in targeting viral expression vectors to ca…”
BackgroundAdenovirus Binding to Blood Factors Results in Liver Cell Infection and Hepatotoxicity
Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z.-Y., & Lieber, A. (2005) · Journal of Virology · doi:10.1128/jvi.79.12.7478-7491.2005 · Cited by 427
“Currently, adenovirus vectors are being used in about one quarter of all gene therapy trials, predominantly for the treatment of cancer (55).”
BackgroundPolymersomes: nature inspired nanometer sized compartments
LoPresti, C., Lomas, H., Massignani, M., Smart, T., & Battaglia, G. (2009) · Journal of Materials Chemistry · doi:10.1039/b818869f · Cited by 416
Shim, M. S., & Xia, Y. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201209633 · Cited by 402
Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems
Guan, S., & Rosenecker, J. (2017) · Gene Therapy · doi:10.1038/gt.2017.5 · Cited by 389
Ouyang, J., Xie, A., Zhou, J., Liu, R., Wang, L., Liu, H., Kong, N., & Tao, W. (2022) · Chemical Society Reviews · doi:10.1039/d1cs01148k · Cited by 385
Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation
Peterson, R. T., Shaw, S. Y., Peterson, T. A., Milan, D. J., Zhong, T. P., Schreiber, S. L., MacRae, C. A., & Fishman, M. C. (2004) · Nature Biotechnology · doi:10.1038/nbt963 · Cited by 384
Kim, M.-H., Na, H.-K., Kim, Y.-K., Ryoo, S.-R., Cho, H. S., Lee, K. E., Jeon, H., Ryoo, R., & Min, D.-H. (2011) · ACS Nano · doi:10.1021/nn103130q · Cited by 364
Advances in Non-Viral DNA Vectors for Gene Therapy
Hardee, C., Arévalo-Soliz, L., Hornstein, B., & Zechiedrich, L. (2017) · Genes · doi:10.3390/genes8020065 · Cited by 356
siRNA-based approaches in cancer therapy
Devi, G. R. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700931 · Cited by 353
Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo
Kalyuzhniy, O., Di Paolo, N. C., Silvestry, M., Hofherr, S. E., Barry, M. A., Stewart, P. L., & Shayakhmetov, D. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711757105 · Cited by 349
“The extreme propensity of the virus for hepatocyte infection after its intravascular delivery has made Ad5 the vector of choice for applications requiring highlevel transgene expression in hepatocytes in vivo (2).”
BackgroundThe spectrum of ocular phenotypes caused by mutations in the BEST1 gene
Boon, C. J. F., Klevering, B. J., Leroy, B. P., Hoyng, C. B., Keunen, J. E. E., & den Hollander, A. I. (2009) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2009.04.002 · Cited by 348
Delivery of therapeutics to the inner ear: The challenge of the blood-labyrinth barrier
Nyberg, S., Abbott, N. J., Shi, X., Steyger, P. S., & Dabdoub, A. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0935 · Cited by 336
“The virulence of certain AAV strains has been problematic for clinical translation in the past due to adverse effects observed in preclinical and clinical trials (67).”
BackgroundHarnessing a High Cargo-Capacity Transposon for Genetic Applications in Vertebrates
Balciunas, D., Wangensteen, K. J., Wilber, A., Bell, J., Geurts, A., Sivasubbu, S., Wang, X., Hackett, P. B., Largaespada, D. A., McIvor, R. S., et al. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020169 · Cited by 335
“Restrictions in cargo-capacity (less than 8 kb) have been reported for integrating viral vectors including retroviruses and lentiviruses [20].”
BackgroundThe Pivotal Role of Vascularization in Tissue Engineering
Auger, F. A., Gibot, L., & Lacroix, D. (2013) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071812-152428 · Cited by 334
Rasines Mazo, A., Allison-Logan, S., Karimi, F., Chan, N. J.-A., Qiu, W., Duan, W., O’Brien-Simpson, N. M., & Qiao, G. G. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00738e · Cited by 329
CRISPR-Cas9 system: A new-fangled dawn in gene editing
Gupta, D., Bhattacharjee, O., Mandal, D., Sen, M. K., Dey, D., Dasgupta, A., Kazi, T. A., Gupta, R., Sinharoy, S., Acharya, K., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116636 · Cited by 323
González-Ballesteros, N., Prado-López, S., Rodríguez-González, J. B., Lastra, M., & Rodríguez-Argüelles, M. C. (2017) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2017.02.020 · Cited by 309
Novel Bioreducible Poly(amido amine)s for Highly Efficient Gene Delivery
Lin, C., Zhong, Z., Lok, M. C., Jiang, X., Hennink, W. E., Feijen, J., & Engbersen, J. F. J. (2007) · Bioconjugate Chemistry · doi:10.1021/bc060200l · Cited by 308
Targeted gene knockout by direct delivery of zinc-finger nuclease proteins
Gaj, T., Guo, J., Kato, Y., Sirk, S. J., & Barbas, C. F. (2012) · Nature Methods · doi:10.1038/nmeth.2030 · Cited by 306
The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis
Jain, A., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.016 · Cited by 304
“Biocompatibility is a major concern because incompatibility could otherwise cause a fatal immunogenic response [60,61].”
BackgroundYang, F., Cho, S.-W., Son, S. M., Bogatyrev, S. R., Singh, D., Green, J. J., Mei, Y., Park, S., Bhang, S. H., Kim, B.-S., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905432106 · Cited by 301
“Combined stem cells and gene therapy may further stimulate angiogenesis by producing desired angiogenic and antiapoptotic factors, but safe and efficient gene delivery to stem cells has been challenging (20, 21).”
BackgroundMarine Origin Polysaccharides in Drug Delivery Systems
Cardoso, M., Costa, R., & Mano, J. (2016) · Marine Drugs · doi:10.3390/md14020034 · Cited by 297
“These systems also have high c sts of production due to complexity in the processing of viral vectors [26].”
BackgroundInfluentialCell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents
Borrelli, A., Tornesello, A., Tornesello, M., & Buonaguro, F. (2018) · Molecules · doi:10.3390/molecules23020295 · Cited by 295
“viral vehicles were used with an excellent efficiency, but with high toxicity and immunogenicity [149].”
Cell-permeable nanobodies for targeted immunolabelling and antigen manipulation in living cells
Herce, H. D., Schumacher, D., Schneider, A. F. L., Ludwig, A. K., Mann, F. A., Fillies, M., Kasper, M.-A., Reinke, S., Krause, E., Leonhardt, H., et al. (2017) · Nature Chemistry · doi:10.1038/nchem.2811 · Cited by 293
Delivering the promise of miRNA cancer therapeutics
Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. P. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.002 · Cited by 288
Gene Therapies for Cancer: Strategies, Challenges and Successes
Das, S. K., Menezes, M. E., Bhatia, S., Wang, X., Emdad, L., Sarkar, D., & Fisher, P. B. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.24791 · Cited by 284
“To prevent CAR-dependent native tropism while simultaneously achieving target-specific infection, Kashentseva et al. (2002) engineered Ads expressing a bi-specific adapter protein comprised of sCAR (soluble CAR) and single-chain fragment variable region (scFv) against the c-erbB-2 oncoprotein, highly expressed in brea…”
BackgroundInfluentialRegulatable gene expression systems for gene therapy applications: progress and future challenges
Goverdhana, S., Puntel, M., Xiong, W., Zirger, J. M., Barcia, C., Curtin, J. F., Soffer, E. B., Mondkar, S., King, G. D., Hu, J., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.022 · Cited by 283
“Also, integration of a gene within random chromatin sites could have the added side effects of oncogene activation, tumor suppressor gene inactivation, or insertional mutagenesis, leading to possible oncogenic transformation in the target cells [32-34].”
BackgroundCell culture assays reveal the importance of retroviral vector design for insertional genotoxicity
Modlich, U., Bohne, J., Schmidt, M., von Kalle, C., Knöss, S., Schambach, A., & Baum, C. (2006) · Blood · doi:10.1182/blood-2005-08-024976 · Cited by 278
“Retroviral (including lentiviral) vectors confer a predictable efficiency of stable transgene insertion with a controlled copy number.(5,6) However, secondary leukemias have been reported in which insertional activation of cellular proto-oncogenes by inserted retroviral vectors represented the initiating event, both i…”
McCormack, M. P., & Rabbitts, T. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032207 · Cited by 278
Farkhani, S. M., Valizadeh, A., Karami, H., Mohammadi, S., Sohrabi, N., & Badrzadeh, F. (2014) · Peptides · doi:10.1016/j.peptides.2014.04.015 · Cited by 273
Bioactive Materials for Bone Regeneration: Biomolecules and Delivery Systems
Szwed-Georgiou, A., Płociński, P., Kupikowska-Stobba, B., Urbaniak, M. M., Rusek-Wala, P., Szustakiewicz, K., Piszko, P., Krupa, A., Biernat, M., Gazińska, M., et al. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00609 · Cited by 269
Wang, T., Upponi, J. R., & Torchilin, V. P. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.013 · Cited by 268
Woll, P. S., Grzywacz, B., Tian, X., Marcus, R. K., Knorr, D. A., Verneris, M. R., & Kaufman, D. S. (2009) · Blood · doi:10.1182/blood-2008-06-165225 · Cited by 268
Engineering Exosomes for Cancer Therapy
Gilligan, K., & Dwyer, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061122 · Cited by 266
“While cell-based therapies are promising, significant safety issues remain in relation to activation of a toxic host immune response [2].”
BackgroundSynergistic nanomedicine by combined gene and photothermal therapy
Kim, J., Kim, J., Jeong, C., & Kim, W. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.018 · Cited by 262
Peng, S., Bie, B., Sun, Y., Liu, M., Cong, H., Zhou, W., Xia, Y., Tang, H., Deng, H., & Zhou, X. (2018) · Nature Communications · doi:10.1038/s41467-018-03650-w · Cited by 261
A Review on Electroporation-Based Intracellular Delivery
Shi, J., Ma, Y., Zhu, J., Chen, Y., Sun, Y., Yao, Y., Yang, Z., & Xie, J. (2018) · Molecules · doi:10.3390/molecules23113044 · Cited by 261
“Miniaturized electroporation is a competitive physical gene delivery candidate, with the benefits of instantaneous delivery process, well-defined delivery dosage, high transfection efficiency, minimal cell damage and being viral-free, circumventing the inherited safety concerns posted by viral vectors [62].”
BackgroundTALEN-based Gene Correction for Epidermolysis Bullosa
Osborn, M. J., Starker, C. G., McElroy, A. N., Webber, B. R., Riddle, M. J., Xia, L., DeFeo, A. P., Gabriel, R., Schmidt, M., Von Kalle, C., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.56 · Cited by 258
Extracellular vesicles as a platform for membrane‐associated therapeutic protein delivery
Yang, Y., Hong, Y., Cho, E., Kim, G. B., & Kim, I. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1440131 · Cited by 258
“viral vectors commonly used in gene therapy can trigger immune responses and may have off-target effects on other cells [135,136].”
BackgroundCancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
Kiaie, S. H., Majidi Zolbanin, N., Ahmadi, A., Bagherifar, R., Valizadeh, H., Kashanchi, F., & Jafari, R. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01478-7 · Cited by 255
“Immunogenicity and cytotoxicity concerns, the risks of reverse genome insertion, transient gene expression control, and vector-size limitations of viral constructs restricted their utilization for long-term therapeutics despite the obvious advantage of efficient delivery due to high-efficiency transfection of host cel…”
BackgroundMesenchymal stem cell‐based therapy: a new paradigm in regenerative medicine
Satija, N. K., Singh, V. K., Verma, Y. K., Gupta, P., Sharma, S., Afrin, F., Sharma, M., Sharma, P., Tripathi, R. P., & Gurudutta, G. U. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00857.x · Cited by 252
“The use of viral vectors because of their high transduction efficiency is likely to be associated with activation of immune responses and problem of insertional mutagenesis despite the development of different generations of viral vectors [128].”
BackgroundMetal–organic frameworks for biological applications
Abánades Lázaro, I., Chen, X., Ding, M., Eskandari, A., Fairen-Jimenez, D., Giménez-Marqués, M., Gref, R., Lin, W., Luo, T., & Forgan, R. S. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00320-8 · Cited by 252
Polymeric Nanoparticles for Nonviral Gene Therapy Extend Brain Tumor Survival in Vivo
Mangraviti, A., Tzeng, S. Y., Kozielski, K. L., Wang, Y., Jin, Y., Gullotti, D., Pedone, M., Buaron, N., Liu, A., Wilson, D. R., et al. (2015) · ACS Nano · doi:10.1021/nn504905q · Cited by 249
“However, viruses pose significant safety risks due to their inherent toxicity, immunogenicity, and tumorigenicity.(14)”
BackgroundGene therapy for cancer: present status and future perspective
Amer, M. H. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-27 · Cited by 244
“Retroviruses including lentiviruses can integrate themselves into host cell genome at the nucleus, while adenoviruses and adenoassociated viruses predominantly persist as extrachromosomal episomes [24,37].”
BackgroundGhazi, N. G., Abboud, E. B., Nowilaty, S. R., Alkuraya, H., Alhommadi, A., Cai, H., Hou, R., Deng, W.-T., Boye, S. L., Almaghamsi, A., et al. (2016) · Human Genetics · doi:10.1007/s00439-016-1637-y · Cited by 243
Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
Carlsten, M., & Childs, R. W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00266 · Cited by 243
“Finally, although the risk may be low, the possibility of viral-induced insertional mutagenesis and immunogenicity (43, 44) occurring post transduction must be considered when utilizing this methodology in the clinic.”
MethodGene delivery using dendrimer-entrapped gold nanoparticles as nonviral vectors
Shan, Y., Luo, T., Peng, C., Sheng, R., Cao, A., Cao, X., Shen, M., Guo, R., Tomás, H., & Shi, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.12.045 · Cited by 242
Yang, Y.-P., Chien, Y., Chiou, G.-Y., Cherng, J.-Y., Wang, M.-L., Lo, W.-L., Chang, Y.-L., Huang, P.-I., Chen, Y.-W., Shih, Y.-H., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.071 · Cited by 240
“potential mutagenesis caused by the random insertion of viral sequences into host chromosomes, limit the clinical applicability of this technique [33].”
BackgroundInfluentialNon-viral gene therapy: Gains and challenges of non-invasive administration methods
Foldvari, M., Chen, D. W., Nafissi, N., Calderon, D., Narsineni, L., & Rafiee, A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.012 · Cited by 238
“While all three classes of viral gene therapy have shown the ability to achieve high level of transgene delivery in various in vivo disease models and clinical trials, the uncertainty of triggering immunogenic responses, transgene mis-insertion risks, problems with large-scale production along with the difficulty of p…”
BackgroundIn vivo gene delivery mediated by non-viral vectors for cancer therapy
Mohammadinejad, R., Dehshahri, A., Sagar Madamsetty, V., Zahmatkeshan, M., Tavakol, S., Makvandi, P., Khorsandi, D., Pardakhty, A., Ashrafizadeh, M., Ghasemipour Afshar, E., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.038 · Cited by 238
“Also, the limited capacity of viruses for gene delivery and expensive production methods of engineered viruses for large-scale production has hampered their application as a promising vector [7,8].”
The spectrum of retinal dystrophies caused by mutations in the peripherin/RDS gene
Boon, C. J. F., den Hollander, A. I., Hoyng, C. B., Cremers, F. P. M., Klevering, B. J., & Keunen, J. E. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.01.002 · Cited by 236
“Moreover, concerns remain about toxic side effects that may be caused by the AAV vector (Thomas et al., 2003; Baum et al., 2006).”
Towards applications of bioentities@MOFs in biomedicine
Velásquez-Hernández, M. D. J., Linares-Moreau, M., Astria, E., Carraro, F., Alyami, M. Z., Khashab, N. M., Sumby, C. J., Doonan, C. J., & Falcaro, P. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213651 · Cited by 233
“Although viral gene delivery achieves high levels of gene expression, it has several disadvantages such as immunogenicity and oncogenicity that make it problematic for clinical trials [258].”
BackgroundSleeping Beauty Transposition: Biology and Applications for Molecular Therapy
Izsvák, Z., & Ivics, Z. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.009 · Cited by 230
“The extended cloning capacity of SB compares favorably to both retrovirus and AAV vectors, which have strict limitations in insert size [2].”
BackgroundInfluentialControlled gene and drug release from a liposomal delivery platform triggered by X-ray radiation
Deng, W., Chen, W., Clement, S., Guller, A., Zhao, Z., Engel, A., & Goldys, E. M. (2018) · Nature Communications · doi:10.1038/s41467-018-05118-3 · Cited by 227
Non-genetic engineering of cells for drug delivery and cell-based therapy
Wang, Q., Cheng, H., Peng, H., Zhou, H., Li, P. Y., & Langer, R. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.003 · Cited by 225
Design of lipid nanoparticles for in vitro and in vivo delivery of plasmid DNA
Kulkarni, J. A., Myhre, J. L., Chen, S., Tam, Y. Y. C., Danescu, A., Richman, J. M., & Cullis, P. R. (2017) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.12.014 · Cited by 225
“Viral vectors are tedious to construct and manufacture, have limited carrying capacity (3) and are often immunogenic (4-6).”
BackgroundTransposon-mediated BAC transgenesis in zebrafish
Suster, M. L., Abe, G., Schouw, A., & Kawakami, K. (2011) · Nature Protocols · doi:10.1038/nprot.2011.416 · Cited by 225
“; however, retroviral vectors have a very limited cargo capacity (”
BackgroundExtracellular Barriers to in Vivo PEI and PEGylated PEI Polyplex-Mediated Gene Delivery to the Liver
Burke, R. S., & Pun, S. H. (2008) · Bioconjugate Chemistry · doi:10.1021/bc700388u · Cited by 221
Peñuelas, I., Mazzolini, G., Boán, J. F., Sangro, B., Martí-Climent, J., Ruiz, M., Ruiz, J., Satyamurthy, N., Qian, C., Barrio, J. R., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.024 · Cited by 220
Polycation cytotoxicity: a delicate matter for nucleic acid therapy—focus on polyethylenimine
Parhamifar, L., Larsen, A. K., Hunter, A. C., Andresen, T. L., & Moghimi, S. M. (2010) · Soft Matter · doi:10.1039/c000190b · Cited by 213
Hepatitis C Virus RNA Replication
Lohmann, V. (2013) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-27340-7_7 · Cited by 213
Efficient Non-Viral Ocular Gene Transfer with Compacted DNA Nanoparticles
Farjo, R., Skaggs, J., Quiambao, A. B., Cooper, M. J., & Naash, M. I. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000038 · Cited by 208
“Although viral vectors also have been successful in alleviating hereditary retinal degeneration in mice [12,21], they can be limited by cell tropism, the size of the expression cassette to be transferred, and host immunity to repeat infections [22,23].”
BackgroundKang, Y. K., Kwon, K., Ryu, J. S., Lee, H. N., Park, C., & Chung, H. J. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00676 · Cited by 208
Tucker, B. A., Mullins, R. F., Streb, L. M., Anfinson, K., Eyestone, M. E., Kaalberg, E., Riker, M. J., Drack, A. V., Braun, T. A., & Stone, E. M. (2013) · eLife · doi:10.7554/elife.00824 · Cited by 207
“For genes such as USH2A, vectors with large carrying capacities such as HSV1, which can accommodate inserts of up to 40 kb in size (Thomas et al., 2003), may be useful.”
Background
Metadata
- Authors
- Thomas, C. E., Ehrhardt, A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Reviews Genetics
- Published
- 2003-05-01
- Volume
- 4
- Issue
- 5
- Pages
- 346-358
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2014356856
- Cited by
- 2,501
- References
- 124
- Citations by year
- 2026: 41 · 2025: 59 · 2024: 110 · 2023: 98 · 2022: 109 · 2021: 116 · 2020: 151 · 2019: 153 · 2018: 150 · 2017: 168 · 2016: 142 · 2015: 143 · 2014: 148 · 2013: 122 · 2012: 109
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Pennsylvania
- Hospital for Sick Children
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- gene therapy, viral vectors, clinical gene therapy, gene therapy safety, retroviral vectors, clinical trials
- MeSH terms
- Dependovirus, Adenoviridae, Defective Viruses, Genetic Vectors, Humans, Neoplasms, Retroviridae, Viruses, Genetic Therapy, Lentivirus, Simplexvirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.